Loading...
XKRX
087010
Market cap2.39bUSD
Apr 11, Last price  
164,700.00KRW
1D
29.99%
1Q
69.10%
Jan 2017
741.38%
IPO
205.00%
Name

Peptron Inc

Chart & Performance

D1W1MN
P/E
—
P/S
1,016.56
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.89%
Rev. gr., 5y
-2.85%
Revenues
3.15b
-5.68%
3,100,534,0003,103,476,7202,483,532,2202,812,386,7713,130,705,2953,215,383,9943,861,733,2101,801,118,5273,120,697,6946,624,511,9635,813,995,5373,341,893,5723,152,181,430
Net income
-22.03b
L+38.39%
-2,559,474,000-2,059,418,400-3,046,281,250-2,730,419,563-3,190,975,867-4,426,816,681-3,725,911,350-17,717,554,794-18,381,916,319-15,041,985,237-15,062,790,476-15,921,881,877-22,033,671,490
CFO
-12.77b
L+16.34%
-958,521,000-1,319,803,030-2,856,433,460-2,355,852,688-2,729,800,627-5,625,535,862-4,180,119,815-9,599,502,080-13,550,207,785-10,614,800,228-11,719,975,876-10,973,481,430-12,766,431,250
Dividend
Mar 15, 20220.285 KRW/sh
Earnings
May 14, 2025

Profile

Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.
URL
http://www.peptron.co.kr/
IPO date
Jul 22, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,152,181
-5.68%
3,341,894
-42.52%
5,813,996
-12.24%
Cost of revenue
17,054,401
16,588,088
19,446,795
Unusual Expense (Income)
NOPBT
(13,902,220)
(13,246,194)
(13,632,800)
NOPBT Margin
Operating Taxes
414,399
(18,937)
(4,206)
Tax Rate
NOPAT
(14,316,619)
(13,227,257)
(13,628,593)
Net income
(22,033,671)
38.39%
(15,921,882)
5.70%
(15,062,790)
0.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
139,067,928
(891,084)
BB yield
-6.65%
0.11%
Debt
Debt current
1,091,750
4,606,890
9,143,948
Long-term debt
8,331,318
4,610,084
163,782
Deferred revenue
8
Other long-term liabilities
3,605,370
3,404,920
2,683,445
Net debt
(3,165,640)
202,409
(11,508,617)
Cash flow
Cash from operating activities
(12,766,431)
(10,973,481)
(11,719,976)
CAPEX
(1,008,298)
(731,086)
(1,715,388)
Cash from investing activities
(127,364,531)
11,038,842
12,073,799
Cash from financing activities
136,784,012
(852,535)
(47,810)
FCF
(1,925,409)
(7,389,375)
(20,712,221)
Balance
Cash
123,896,802
4,982,736
17,242,834
Long term investments
(111,308,093)
4,031,830
3,573,513
Excess cash
12,431,100
8,847,471
20,525,647
Stockholders' equity
(1,888,889)
21,270,100
37,639,232
Invested Capital
166,438,860
39,817,449
44,493,009
ROIC
ROCE
EV
Common stock shares outstanding
20,553
20,581
20,627
Price
101,800.00
152.92%
40,250.00
426.14%
7,650.00
-31.08%
Market cap
2,092,343,551
152.58%
828,396,359
424.98%
157,795,425
-31.08%
EV
2,089,177,911
828,598,768
146,286,809
EBITDA
(11,211,142)
(10,351,879)
(8,578,396)
EV/EBITDA
Interest
472,880
396,039
279,660
Interest/NOPBT